<![CDATA[Epcoritamab/R-CHOP Shows PFS Benefit in Newly Diagnosed DLBCL]]>

Data ReadoutpositiveEpcoritamabR-CHOPPositive

AI Analysis

Summary

Epcoritamab combined with R-CHOP demonstrated a 51% reduction in progression or death risk in newly diagnosed DLBCL patients. This positive data readout supports the therapeutic potential of the drug combination in this indication.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

51% reduction in risk of progression or death when epcoritamab added to R-CHOP in newly diagnosed DLBCL

Importance:7/10

Sentiment:

0.85

oncologylymphomaDLBCLcombination therapyPFS benefit

Related Companies

$GMAB

Read the original article

Published by Cancer Network on October 6, 2026 3:00 PM

Read Original